Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients

Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients

BackgroundProgrammed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors works by reactivating immune cells. Considering the accessibility of noninvasive liquid biopsies, it is advisable to employ peripheral blood lymphocyte subsets to predict immunotherapy outcomes.MethodsWe...

Full description

Bibliographic Details
Main Authors: Ruixuan Geng, Hui Tang, Tingting You, Xiuxiu Xu, Sijian Li, Zepeng Li, Yuan Liu, Wei Qiu, Na Zhou, Ningning Li, Yuping Ge, Fuping Guo, Yuhong Sun, Yingyi Wang, Taisheng Li, Chunmei Bai
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Immunology
Subjects:
programmed cell death-1
lymphocyte subsets
CD8+CD28+ T cell
prognosis
immune-related adverse events
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1125876/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1125876/full

Similar Items